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Abstract
The management of high-risk cutaneous squamous cell carcinoma (cSCC) can be a challenge as evidence from high
quality clinical trials is rare. Guideline developers are challenged to provide practical and useful guidance for clinicians
even in the absence of good evidence. In order to compare treatment recommendations for high-risk and advanced
cSCC among national and international guidelines and to extract the most precise guidance provided, a systematic
search was carried out in guideline databases Medline and Embase with a cutoff of 4 March 2019. Treatment recommen-
dations for predefined clinical scenarios were extracted from selected guidelines and compared qualitatively. Five guide-
lines published from 2015 to 2018 were included. Excision of high-risk tumours with margin assessment was
recommended in all guidelines. A safety margin of at least 6 mm was suggested in four guidelines. There was no clear
recommendation to perform a sentinel lymph node biopsy in any guideline. Lymph node dissection was uniformly rec-
ommended in the presence of nodal disease. Treatment for metastatic cSCC was poorly characterized and restricted to
the use of chemotherapy and epidermal growth factor receptor inhibitors. Recommendations for the management of
high-risk and advanced cSCC were limited. We propose that guidelines should be updated to reflect recent advances in
checkpoint blockade for metastatic cSCC.
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Cutaneous squamous cell carcinoma (cSCC) is a common form
of skin cancer. Accordingly, a considerable number of national
and international guidelines exist for the treatment of cSCC.
Lymphogenic or haematogenic metastasis occurs in a minority
of patients. Thus, larger studies and treatment recommendations
are limited, especially in advanced stages of the disease. Further-
more, the management of cSCC is subject to country-specific
healthcare conditions, which must be taken into consideration.
In this article, we compare the recommendations of guidelines
which are based on a systematic literature search to set an
evidence-based framework for global decision-making in
patients with high-risk or advanced cSCC.
Methods
Eligibility criteria
Published national and international guidelines that included
recommendations for the treatment and management of patients
with advanced or high-risk cSCC were eligible. The guidelines
had to state that they were based on a systematic literature
review and to express at least one recommendation for one of
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the following clinical scenarios of interest: (i) surgical removal of
the primary tumour, (ii) treatment of unresectable cSCC, (iii)
the performance of sentinel lymph node biopsy (SLNB) in high-
risk tumours, (iv) indications for radiation therapy, (v) manage-
ment of lymph node metastases, as well as (vi) systemic inter-
ventions for metastatic disease (Table 1). In order to provide a
synopsis of the most recent and up-to-date recommendations,
we only included guidelines that had not yet expired or are not
about to expire in the year 2019. We also excluded guidelines
published before 2012 or which did not provide any information
on their validity date. Guidelines had to be published in English
or German.
Search strategy and guideline selection
A systematic search for guidelines was carried out in guideline
databases, including multidisciplinary guideline providers and
subject-specific guideline providers (Table S1). The key search
terms included ‘squamous cell carcinoma’ and the German
translation ‘Plattenepithelkarzinom’. Additionally, Medline and
Embase (both via Ovid) were searched until 4 March 2019. The
detailed search strategy is presented in Table S2. Two authors
(MVH, TS) independently screened the titles and abstracts of
the records that were identified in the databases for eligibility.
For records that were considered potentially relevant, the full-
text guidelines were obtained, and the inclusion and exclusion
criteria were applied. Whenever discrepancies arose, resolution
was achieved by discussion with a third independent author
(CB, AN).
Collection, synthesis and management of the
recommendations
Information on each included guideline regarding country of
origin, publication date, approach to classify the evidence for the
recommendations, as well as the recommendations of interest
and their corresponding levels of evidence were collected and
summarized by two authors independently (TS, MVH) to an
extraction spreadsheet using Microsoft Excel 2010. The recom-
mendations on the clinical key questions were extracted to the
spreadsheet and compared qualitatively.
Results
Guideline identification
Our search in the databases and additional references revealed
1571 records (Fig. 1). After title and abstract screening and
removal of duplicates, 14 records underwent full-text review.
Two records were excluded since they were still in development
or unpublished at the time of the search1,2 and one more dupli-
cate was identified.3 Three guidelines were excluded as they were
outdated.4–6 One guideline was only available as a presentation
of an update and identifying clear-cut recommendations was dif-
ficult as no accompanying narrative was provided. Furthermore,
it had a preliminary character at the time of assessment.7 Two
more records were ineligible as they either summarized the
results of different guidelines or did not provide any recommen-
dations.8,9 Hence, five relevant guidelines were included in this
comparison.10–14
Information and methodology of the guidelines
The publication date of the guidelines ranged from 2015 to
2018. Guidelines were available from consortia of the United
States of America (US),10 Canada,11 the United Kingdom
(UK),13 and Europe.12,14 The Italian Guideline from Peris
et al.14 was adapted from and updated the European guideline.
The guidelines used distinct approaches to grade the level of evi-
dence and to express the strength of their recommendations,
limiting the cross-guideline comparability. The Canadian guide-
line used the GRADE approach to rate the certainty of the evi-
dence.11 For the guideline from the US, available evidence was
evaluated with a unified system called the ‘Strength of Recom-
mendation Taxonomy’ on a 3-tier-scale based on the quality of
study methodology, and the overall focus of the study.10 The UK
guideline labelled their evidence-based recommendations with-
out a grade attached indicated by ‘(R)’, and those based on clini-
cal experience as a good practice point ‘(G)’.13,15 Both the
European and Italian guidelines stated that a literature review
had been performed; however, they did not provide any explana-
tion of whether they had assessed the level of evidence of their
recommendations.12,14
Definition of high-risk cSCC
The risk of metastasis formation from cSCC is usually low and
only a minority of patients develops lymphogenic or haemato-
genic metastasis during the course of the disease. A definition of
high-risk cSCC is, therefore, of paramount importance to iden-
tify patients at risk early and to provide them with more inten-
sive therapy and closer follow-up. High-risk features were
specified in all of the included guidelines and can be divided into
histological and clinical factors. Histological prognostic factors
consistently reported in the guidelines were a poor differentia-
tion according to the Broders classification and desmoplasia of
the tumour, high vertical invasion depth (>2–4 mm) or Clark
level (IV, V), perineural spread and lymphovascular invasion.
Clinical factors were a horizontal extension >20 mm, poorly
defined borders of the tumour, status after local recurrence,
rapid tumour growth, neurological symptoms, and immunosup-
pression. However, all guidelines admit that the definition of
these risk factors was mainly based on retrospective studies such
as observational studies and case series and that only a few
prospective studies exist which investigate high-risk features in a
prospective and controlled fashion. In the following, critical clin-
ical scenarios for high-risk tumours are presented and the rec-
ommendations from the included guidelines are compared
qualitatively.
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Management of the primary tumour site
An important question on the management of the primary
tumour site is how high-risk tumours should be treated surgi-
cally in contrast to low-risk ones. One possibility is excision
with subsequent conventional histological processing of the
specimen in the bread loaf technique or with postoperative
margin assessment. These methods were mentioned for high-
risk cSCC in all five guidelines, but evaluated differently, as the
strength of the recommendation varied from high (‘treatment
of choice’)12 to low (‘may be considered’).10 In four of five of
the analyzed guidelines, safety margins for excision were speci-
fied. For high-risk tumours, they were recommended to be at
least 6 mm throughout all guidelines (>6 mm13; 6–13 mm11;
>10 mm12; 10 mm14). Removal by Moh’s micrographic surgery
with a complete examination of the margins was recommended
and classified as a method of choice for high-risk tumours in
three guidelines.10–12 In contrast, the UK guideline made only a
weak recommendation for Moh’s (‘has a role in some high-risk
cSCC’), and only after discussion in a multidisciplinary set-
ting.13 The use of curettage with or without electrodesiccation
was explicitly discouraged in one guideline and not considered
indicated in recurrent or high-risk cSCC.13 Similarly, two other
guidelines recommended this procedure for low-risk tumours
only.10,11 Postoperative radiotherapy was unanimously recom-
mended in three guidelines if the resection status is incomplete
and complete removal of the tumour cannot be achieved with
surgery for functional or anatomic reasons. Furthermore, three
guidelines made an explicit recommendation for postoperative
radiotherapy in case of perineural invasion.11,12,14
Performance and indication of sentinel lymph node biopsy
As the next relevant clinical question, we analyzed the recom-
mendations for performing SLNB. In two of five guidelines, the
topic was discussed but no specific recommendations were
given. The authors stated that the significance of performing
SLNB was either unknown or that the procedure was only used
within studies and had no role in routine clinical care.10,13 Two
studies included recommendations that did not represent a con-
crete mandate for action and should therefore be regarded as
statements. They concluded that there was either no or only
inconclusive data regarding the indication for SLNB.12,14 One
guideline recommended SLNB as an optional procedure that
may be offered to a selected high-risk population after discus-
sion in a multidisciplinary team.11 However, the strength of this
recommendation was weak (‘may be considered’) and the level
of evidence low.11 Overall, the indication for SLNB even in the
high-risk situation was poorly characterized and no specific
criteria were proposed for the decision to perform (or not) SLNB.
This uncertainty may be due to the lack of evidence regarding this
scenario and contrasts sharply with other skin cancer entities such
as melanoma and Merkel cell carcinoma where the role of SLNB
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Management of nodal metastases
In the presence of loco-regional metastases of cSCC, unequivocal
recommendations were identified in most guidelines. Four of
five studies strongly recommended a complete dissection of
regional lymph nodes in case of detection of metastasis.10,12–14
Moreover, two guidelines recommended adjuvant radiotherapy
following complete dissection,10,12 if multiple lymph nodes were
affected or extracapsular tumour growth was detected.13 If the
parotideal gland was affected by metastasis, a parotidectomy was
explicitly recommended in two guidelines.13,14 The strength of
the recommendation was consistently high (‘recommended
treatment’10,12,14; ‘should be performed’13).
Management of advanced cSCC
Advanced cSCC was defined as locally unresectable disease or
as metastatic spread to distant organs. If the primary tumour
cannot be removed surgically due to its extent or in case of
contraindications to surgery, two guidelines mentioned pri-
mary radiotherapy as an alternative with a medium strength
of recommendation (‘should be considered’).10,11 The US
guideline suggested a combination of chemotherapy as
‘chemoradiation’ for inoperable disease.10 For metastatic (stage
IV) disease, three of five guidelines did not make a specific
recommendation.11,13,14 One study emphasized the role of cis-
platin and inhibitors of the epidermal growth factor receptor
(EGFR), either as a single agent or as combination therapy.10
However, the strength of recommendation was low (‘may be
considered’) and only limited data were available to support
this statement.10 Similarly, the European guideline stated that
mono- or poly-chemotherapy can be used in metastatic cSCC,
although responses are usually short-lived and no standard
regimen exists. The use of EGFR inhibitors was encouraged in
clinical trials in this guideline.12
Discussion and concluding remarks
In this comparative analysis, we systematically searched for pub-
lished guidelines on cSCC and evaluated the treatment recom-
mendations for high-risk and advanced disease for defined
clinical scenarios. A major limitation was the fact that the guide-
lines used different approaches to rate the level of evidence and
to make treatment recommendations, limiting the cross-guide-
line comparability. Nevertheless, all studies uniformly recom-
mended excision of high-risk primary tumours with a safety
margin of at least 6 mm or with Moh’s micrographic surgery.
However, it remains unclear from our analysis whether and
when SLNB should be performed. Thus, in patients with high-
risk features, the decision to perform an SLNB remains to be dis-
cussed individually and the lack of evidence should be explicitly
addressed. Interestingly, recommendations for advanced cSCC
were found in only two of the included guidelines.10,12 The
strength of the recommendation was low, underlining that the
treatment options are limited in this situation. None of the
guidelines mentioned the use of immune checkpoint blockade in
metastatic disease, which has most recently shown encouraging
results in various studies.16–18 Inhibitors of PD-1 such as pem-
brolizumab or nivolumab may be applied off-label, while cemi-
plimab was approved for metastatic cSCC in the US and in
Europe based on a phase II trial.19–22 In this context, NICE has
published their recommendation to reimburse cemiplimab for
this indication.2 We hypothesize that these agents will
Additional records identified 
through other sources (n = 8)
Records identified 
(n = 1571)






Full-text articles excluded (n = 9)
• n = 2 (in development)
• n = 1 (duplicate)
• n = 3 (expired)
• n = 1 (only available as presentation)
• n = 1 (no recommendations)
• n = 1 (summary of guidelines)
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Figure 1 PRISMA flowchart of the study. Selection process for study inclusion in the systematic review according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).
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significantly improve the prognosis and change the standard of
care for advanced cSCC. We conclude that national and interna-
tional treatment guidelines should be updated and make specific
recommendations for the use of checkpoint blockade in
advanced cSCC.
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